ClinConnect ClinConnect Logo
Search / Trial NCT03653156

China Cognition and Aging Study

Launched by CAPITAL MEDICAL UNIVERSITY · Aug 29, 2018

Trial Information

Current as of July 01, 2025

Recruiting

Keywords

ClinConnect Summary

The China Cognition and Aging Study (China COAST) is a research project aimed at understanding dementia, including conditions like Mild Cognitive Impairment (MCI), Alzheimer’s Disease, and Vascular Dementia, among others. The study seeks to gather valuable information about how common these conditions are in China, what causes them, and how they can be diagnosed and treated. Researchers plan to collect data over several years from a wide range of participants, including healthy individuals and those with cognitive issues, to build a comprehensive database. This information will help improve the understanding and management of dementia in the future.

To participate, individuals must be at least 55 years old and provide consent. Those diagnosed with MCI or various forms of dementia, as well as healthy individuals, are welcome to join. Participants can expect to undergo assessments that may include tests of memory and thinking, brain scans, and blood samples. The study also aims to explore lifestyle factors that could help prevent dementia, as well as the emotional and social challenges faced by patients and their caregivers. Overall, this research is crucial for developing better strategies to combat cognitive disorders in China.

Gender

ALL

Eligibility criteria

  • Community population: age ≥ 55 years, male or female, with consent to participant the study.
  • Hospital population: subjects are all over 18 years old. Through clinical evaluation, neuropsychological test, imaging examination, blood and cerebrospinal fluid examination, etc, we will comprehensively evaluate the cognitive function and various test measures.
  • (1) MCI and its subtypes
  • Inclusion criteria:
  • 1. Diagnosis according to 2004 Peterson's MCI criteria.
  • 2. CDR = 0.5.
  • 3. Memory loss is prominent, and may also be with other cognitive domain dysfunction.
  • 4. Insidious onset, slow progress.
  • 5. Not reaching the level of dementia.
  • Exclusion criteria:
  • 1. With history of stroke and a neurological focal sign, the imaging findings are consistent with cerebral small vessal disease (Fazekas score ≥ 2 points).
  • 2. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).
  • 3. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).
  • 4. Mental and neurodevelopmental retardation.
  • 5. Contraindications to MRI.
  • 6. Suffering from a disease that cannot be combined with cognitive examination.
  • 7. Refuse to draw blood.
  • 8. Refuse to sign the informed consent at baseline
  • (2) Sporadic Alzheimer's disease (SAD)
  • Inclusion criteria:
  • 1. Dementia is diagnosed according to the criteria described by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R). The diagnosis of AD is made using the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) or National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria.
  • 2. Subjects and their informed persons can complete relevant and follow- up examinations.
  • 3. Subjects or their authorized legal guardians sign the informed consent.
  • Exclusion criteria:
  • 1. With a family history of dementia.
  • 2. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).
  • 3. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).
  • 4. Mental and neurodevelopmental retardation.
  • 5. Contraindications to MRI.
  • 6. Suffering from a disease that cannot be combined with cognitive examination.
  • 7. Refuse to draw blood.
  • 8. Refuse to sign the informed consent at baseline
  • (3) Familial Alzheimer's disease (FAD)
  • Inclusion criteria:
  • 1. Written informed consent obtained from participant or legal guardian prior to any study-related procedures.
  • 2. Members in FAD pedigree (FAD is defined as at least two first- degree relatives suffer from AD).
  • 3. Aged 18 (inclusive) or older.
  • 4. At least two persons who can provide reliable information for the study. Note: Dementia is diagnosed according to the criteria described by DSM-IV-R. The diagnosis of AD is made using NINCDS-ADRDA or NIA-AA criteria. A diagnosis of MCI is assigned according to Petersen criteria.
  • Exclusion criteria:
  • 1. Dementia caused by other factors such as depression, other psychiatric illnesses, thyroid dysfunction, encephalitis, multiple sclerosis, brain trauma, brain tumor, syphilis, acquired immunodeficiency syndrome (AIDS), Creutzfeldt-Jakob disease and other types of dementias such as vascular dementia (VaD), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), and Parkinson's disease dementia (PDD).
  • 2. MRI and laboratory tests do not support or rule out a diagnosis of AD.
  • 3. Severe circulatory, respiratory, urinary, digestive, hematopoietic diseases (such as unstable angina, uncontrollable asthma, active gastric bleeding) and cancer.
  • 4. Participant has severe psychiatric illness or severe dementia that would interfere in completing initial and follow-up clinical assessments.
  • 5. With history of alcohol or drug abuse.
  • 6. Pregnant or lactating women.
  • 7. No reliable insiders.
  • 8. Refuse to sign the informed consent at baseline.
  • (4) Vascular dementia (VaD)
  • Inclusion criteria:
  • Diagnosis for probable VaD according to NINDS-AIREN diagnostic criteria.
  • MRI inclusion criteria:
  • All patients who meet clinical inclusion criteria should accept MRI scans which include an assessment of hippocampal volume.
  • 1. multiple (≥3) supratentorial subcortical small infarcts (3-20 mm in diameter) with or without any degree of white matter lesion (WML); or moderate to severe WML (Fazekas score ≥ 2), with or without small infarction; or ≥ 1 subcortical small infarct in key regions, such as caudate nucleus, globus pallidus, or thalamus.
  • 2. no cortical and watershed infarction, hemorrhage, hydrocephalus, or WML with specific causes (such as multiple sclerosis).
  • 3. no hippocampus or entorhinal cortex atrophy (MTA score = 0 point).
  • Exclusion criteria:
  • 1. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).
  • 2. Other systemic diseases that can cause cognitive impairment (such as liver insufficiency, renal insufficiency, thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).
  • 3. With a history of mental illness or those with congenital mental retardation.
  • 4. Suffering from a disease that cannot be combined with a cognitive examination.
  • 5. Contraindications to MRI.
  • 6. Refuse to draw blood.
  • 7. Refuse to sign informed consent.
  • (5) Normal control
  • Inclusion criteria:
  • 1. Aged 18 (inclusive) or above.
  • 2. Normal MMSE and MoCA evaluations. MMSE\>19 points for illiteracy, \>24 points for those educated less than 7 years, \>27 points for those educated equal to or more than 7 years. MoCA\>13 points for illiteracy, \>19 points for those educated less than 7 years, \>24 points for those educated equal to or more than 7 years.
  • Exclusion criteria:
  • 1. Subjects with abnormal MMSE or MoCA scores.
  • 2. Subjects with a history of cerebral infarction, traumatic brain injury or related manifestations in MRI.
  • 3. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).
  • 4. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).
  • 5. Mental and neurodevelopmental retardation.
  • 6. Suffering from a disease that cannot be combined with a cognitive examination.
  • 7. Contraindications to MRI.
  • 8. Refuse to draw blood.
  • 9. Refuse to sign the informed consent at baseline.

About Capital Medical University

Capital Medical University is a leading institution in medical education and research, dedicated to advancing healthcare through innovative clinical trials. With a strong emphasis on scientific rigor and ethical standards, the university collaborates with a network of healthcare professionals and researchers to drive breakthroughs in medical science. Capital Medical University aims to enhance patient care and improve health outcomes by fostering a multidisciplinary approach to clinical research, ensuring that its trials are designed to address critical health challenges and contribute valuable insights to the medical community.

Locations

Zhengzhou, Henan, China

Nanning, Guangxi, China

Jinan, Shandong, China

Wuhan, Hubei, China

Hefei, Anhui, China

Changchun, Jilin, China

Yinchuan, Ningxia, China

Hangzhou, Zhejiang, China

Hangzhou, Zhejiang, China

Qingdao, Shandong, China

Shenyang, Liaoning, China

Nanchang, Jiangxi, China

Dalian, Liaoning, China

Qingdao, Shandong, China

Guiyang, Guizhou, China

Taiyuan, Shanxi, China

Nanchong, Sichuan, China

Handan, Hebei, China

Changping, Beijing, China

Chaoyang, Beijing, China

Chaoyang, Beijing, China

Fengtai, Beijing, China

Haidian, Beijing, China

Haidian, Beijing, China

Haidian, Beijing, China

Xicheng, Beijing, China

Xicheng, Beijing, China

Yuzhong, Chongqing, China

Yuzhong, Chongqing, China

Fujian, Guangdong, China

Guangzhou, Guangdong, China

Zhongshan, Guangdong, China

Shijiazhuang, Hebei, China

Tangshan, Hebei, China

Zhijiazhuang, Hebei, China

Haerbin, Heilongjiang, China

Kaifeng, Henan, China

Zhengzhou, Henan, China

Wuhan, Hubei, China

Wuhan, Hunan, China

Wuhan, Hunan, China

Wuhan, Hunan, China

Nantong, Jiangsu, China

Subei, Jiangsu, China

Xuzhou, Jiangsu, China

Changchun, Jilin, China

Anshan, Liaoning, China

Dalian, Liaoning, China

Baotou, Nei Monggol, China

Yinchuan, Ningxia, China

Jining, Shandong, China

Qingdao, Shandong, China

Tai'an, Shandong, China

Huangpu, Shanghai, China

Luwan, Shanghai, China

Putong, Shanghai, China

Xi'an, Shanxi, China

Xi'an, Shanxi, China

Zigong, Sichuan, China

Heping, Tianjin, China

Jinnan, Tianjin, China

Urumqi, Xinjiang, China

Hangzhou, Zhejiang, China

Ningbo, Zhejiang, China

Wenzhou, Zhejiang, China

Patients applied

0 patients applied

Trial Officials

Jianping Jia, Doctor

Study Chair

Xuanwu Hospital of Capital Medical University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials